[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
Running, not enrolling · Phase 1
Conditions studied: Breast Cancer
In brief
The purpose of this trial is to estimate the recommended dose (RD) of \[177Lu\]Lu-NeoB in combination with ribociclib and fulvestrant in participants with estrogen receptor (ER) positive (ER+), human epidermal growth factor receptor-2 (HER2) negative (HER2-) and gastrin releasing peptide receptor (GRPR) positive (GRPR+) advanced breast cancer experiencing early relapse from (neo)adjuvant endocrine therapy or who have progressed on endocrine therapy in combination with a CDK4/6 inhibitor for advanced disease.
Key facts
- Study ID
- NCT05870579
- Run by
- Novartis Pharmaceuticals
- People needed
- 28
- Starts
- 2023-11-13
- Expected to finish
- 2032-04-27
- Last updated by the study team
- 2026-07-06
Who can join
Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UCLA Jonsson Comp Cancer Center — Los Angeles, California, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Novartis Investigative Site — Shanghai, China
- Novartis Investigative Site — Saint-Cloud, Hauts De Seine, France
- Novartis Investigative Site — Bordeaux, France
- Novartis Investigative Site — Saint-Herblain, France
- Novartis Investigative Site — Cologne, North Rhine-Westphalia, Germany
- Novartis Investigative Site — Gliwice, Poland
- Novartis Investigative Site — Porto, Portugal
- Novartis Investigative Site — L'Hospitalet de Llobregat, Barcelona, Spain
- Novartis Investigative Site — Barcelona, Spain
- Novartis Investigative Site — Madrid, Spain
- Novartis Investigative Site — Madrid, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.